查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529640

静脉注射铁剂市场规模、份额、趋势分析报告：按产品、按应用、按地区、细分市场预测，2024-2030

Intravenous Iron Drugs Market Size, Share & Trends Analysis Report By Product (Iron Sucrose, Iron Dextran, Ferric Carboxymaltose), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

静脉注射铁剂市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2024年至2030年全球静脉注射注射铁剂市场将以9.2%的复合年增长率成长，2030年达到56.2亿美元。

预计在预测期内，行业竞争将保持在较高水平。全球公司占据了大部分市场收益占有率。此外，成长机会吸引新参与企业，进一步加剧竞争对手之间的竞争。市场已细分，领先公司正在采取广泛的成长策略，包括策略联盟、收购和新药上市，以获取更大的份额。

感染疾病造成的高疾病负担加上营养不良是该地区儿童贫血的主要原因之一。冠状病毒大流行也加剧了重症患者的贫血，在某些情况下甚至导致缺氧。这进一步增加了世界各地对治疗贫血的铁补充剂的需求。

贫血盛行率的增加也是由各种妇科和胃肠道疾病引起的，促使静脉注射治疗在世界普及。例如，同年龄层非孕妇贫血总体盛行率为29.6%，孕妇贫血总体盛行率为36.5%。由于医疗保健预算增加和投资增加，预计市场在预测期内将大幅成长。

口服铁剂的缺点，包括消化器官系统问题，如胃痛、便秘、食慾不振、噁心和呕吐，是患者偏好静脉注射铁剂的原因。静脉注射补充铁已被证明可以增加体内铁的吸收，促进红血球生成刺激因子（ESA）的作用，并改善贫血状况。其他好处包括保持心臟健康以及透析患者（尤其是接受血液透析机的患者）使用它。

静脉注射注射铁剂市场报告亮点

  • Ferric carboxymaltose因其用量不断增加、性能优越、副作用较少且成本较低，在 2023 年占据静脉铁剂行业的主导地位。
  • 2023年蔗糖铁在市场中占有较大份额。严重过敏反应的发生率较低，提高了这些药物的采用率。
  • 由于 CKD 和 CKD 相关缺铁性贫血病例的盛行率不断增加，2023 年慢性肾臟病市场所占份额最大。
  • 由于静脉注射药物的高需求以及胃肠道疾病、癌症和 CKD 盛行率的增加，2023 年北美将占据最大的区域份额。
  • 在估计和预测期内，由于未满足的需求增加、医疗保健成本上升以及成熟的跨国公司向该地区扩张，亚太地区预计将成长最快。
  • 主要参与企业包括AbbVie Inc.、AMAG Pharmaceuticals (Covis Pharma)、第一三共株式会社、赛诺菲、Vifor Pharma Management Ltd. (CSL)、PHARMAC、Pharmaceuticals Inc. (CSL)、PHARMACOSMOS A/S、Zydus Group、 ETC。

目录

第一章调查方法和范围

第二章执行概述

第三章 静脉注射铁剂市场-产业展望

  • 市场体系展望
  • 市场动态
  • 波特五力分析
  • PESTLE分析
  • COVID-19 影响分析

第 4 章 静脉注射铁剂市场 - 按产品細項分析，2018-2030 年（百万美元）

  • 静脉注射铁剂市场：产品波动分析
  • 副产品
    • 聚葡萄糖铁
    • 蔗糖铁
    • Ferric carboxymaltose
    • 其他的

第五章静脉铁剂市场 - 細項分析，按应用，2018-2030 年（百万美元）

  • 静脉铁剂市场：应用变化分析
  • 按用途

第六章 静脉注射铁剂市场：区域估算及趋势分析

  • 静脉铁剂市场：区域展望
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
    • 资金筹措
  • 2022年主要企业市场占有率分析
  • 公司简介
    • Allergan, Inc.
    • AMAG Pharmaceuticals. Inc.
    • Daiichi Sankyo Company, Ltd.
    • Sanofi
    • Fresenius Medical Care AG &Co.
    • Vifor Pharma Management Ltd.
    • Pharmacosmos A/S
    • Rockwell Medical, Inc.

第8章结论

Product Code: GVR-4-68038-000-2

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2023 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost
  • Iron sucrose held a significant share of the market in 2023. A low rate of severe allergic reactions has increased the adoption rate of these drugs
  • The chronic kidney disease segment held the largest share in 2023, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases
  • North America held the largest regional share in 2023 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD
  • Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players
  • Key players include AbbVie Inc.; AMAG Pharmaceuticals (Covis Pharma); Daiichi Sankyo Company, Ltd.; Sanofi; Vifor Pharma Management Ltd. (CSL); PHARMACOSMOS A/S; Zydus Group

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Regional Scope
    • 1.1.2 Market Definitions
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Objectives
    • 1.2.1 Objective - 1
    • 1.2.2 Objective - 2
    • 1.2.3 Objective - 3
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary research
    • 1.4.5 Sample size for the study on Intravenous Iron Drugs Market:
  • 1.5 Information or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation and Validation
  • 1.7 Market Model
    • 1.7.1 Market study, by Company Market Share
    • 1.7.2 Commodity Flow Analysis
      • 1.7.2.1 Approach 1: Commodity Flow Approach
      • 1.7.2.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
    • 1.7.3 Regional analysis
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Abbreviations

Chapter 2 EXECUTIVE SUMMARY

  • 2.1 Market Snapshot, 2023
  • 2.2 Segment Snapshot
  • 2.3 Competitive Snapshot

Chapter 3 Intravenous Iron Drugs Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market
    • 3.1.2 Related/Ancillary Market Outlook
      • 3.1.2.1 Inflammatory Bowel Disease Treatment Market
      • 3.1.2.2 Anemia Treatment Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers
      • 3.2.1.1 Increasing prevalence of target diseases
      • 3.2.1.2 Rising prevalence of iron deficiency anemia
      • 3.2.1.3 Advantages of intravenous iron drugs
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Adverse effects associated with iron drugs
      • 3.2.2.2 Increasing approvals of oral iron drugs
  • 3.3 PORTER'S Five Forces Analysis
  • 3.4 PESTLE Analysis
  • 3.5 COVID-19 Impact Analysis

Chapter 4 Intravenous Iron Drugs Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

  • 4.1 Intravenous Iron Drugs Market: Product Movement Analysis
  • 4.2 Intravenous Iron Drugs Market Estimates & Forecast, by Product (USD Million)
    • 4.2.1 Iron Dextran
    • 4.2.2 Iron Sucrose
    • 4.2.3 Ferric Carboxymaltose
    • 4.2.4 Others

Chapter 5 Intravenous Iron Drugs Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

  • 5.1 Intravenous Iron Drugs Market: Application Movement Analysis
  • 5.2 Intravenous Iron Drugs Market Estimates & Forecast, by Application (USD Million)
    • 5.2.1 Chronic Kidney Disease
    • 5.2.2 Inflammatory Bowel Disease
    • 5.2.3 Cancer
    • 5.2.4 Other Diseases

Chapter 6 Intravenous Iron Drugs Market: Regional Estimates and Trend Analysis

  • 6.1 Intravenous Iron Drugs Market: Regional Outlook
  • 6.2 North America
    • 6.2.1 North America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 Key Country Dynamics
      • 6.2.2.2 U.S. Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.2.2.3 Target Disease Prevalence
      • 6.2.2.4 Market & Competitive Scenario
      • 6.2.2.5 Regulatory Framework
      • 6.2.2.6 Reimbursement Scenario
    • 6.2.3 Canada
      • 6.2.3.1 Key Country Dynamics
      • 6.2.3.2 Canada Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.2.3.3 Target Disease Prevalence
      • 6.2.3.4 Market & Competitive Scenario
      • 6.2.3.5 Regulatory Framework
      • 6.2.3.6 Reimbursement Scenario
  • 6.3 Europe
    • 6.3.1 Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 UK
      • 6.3.2.1 Key Country Dynamics
      • 6.3.2.2 UK Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.2.3 Target Disease Prevalence
      • 6.3.2.4 Market & Competitive Scenario
      • 6.3.2.5 Regulatory Framework
      • 6.3.2.6 Reimbursement Scenario
    • 6.3.3 Germany
      • 6.3.3.1 Key Country Dynamics
      • 6.3.3.2 Germany Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.3.3 Target Disease Prevalence
      • 6.3.3.4 Market & Competitive Scenario
      • 6.3.3.5 Regulatory Framework
      • 6.3.3.6 Reimbursement Scenario
    • 6.3.4 France
      • 6.3.4.1 Key Country Dynamics
      • 6.3.4.2 France Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.4.3 Target Disease Prevalence
      • 6.3.4.4 Market & Competitive Scenario
      • 6.3.4.5 Regulatory Framework
      • 6.3.4.6 Reimbursement Scenario
    • 6.3.5 Italy
      • 6.3.5.1 Key Country Dynamics
      • 6.3.5.2 Italy Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.5.3 Target Disease Prevalence
      • 6.3.5.4 Market & Competitive Scenario
      • 6.3.5.5 Regulatory Framework
      • 6.3.5.6 Reimbursement Scenario
    • 6.3.6 Spain
      • 6.3.6.1 Key Country Dynamics
      • 6.3.6.2 Spain Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.6.3 Target Disease Prevalence
      • 6.3.6.4 Market & Competitive Scenario
      • 6.3.6.5 Regulatory Framework
      • 6.3.6.6 Reimbursement Scenario
    • 6.3.7 Denmark
      • 6.3.7.1 Key Country Dynamics
      • 6.3.7.2 Denmark Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.7.3 Target Disease Prevalence
      • 6.3.7.4 Market & Competitive Scenario
      • 6.3.7.5 Regulatory Framework
      • 6.3.7.6 Reimbursement Scenario
    • 6.3.8 Sweden
      • 6.3.8.1 Key Country Dynamics
      • 6.3.8.2 Sweden Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.8.3 Target Disease Prevalence
      • 6.3.8.4 Market & Competitive Scenario
      • 6.3.8.5 Regulatory Framework
      • 6.3.8.6 Reimbursement Scenario
    • 6.3.9 Norway
      • 6.3.9.1 Key Country Dynamics
      • 6.3.9.2 Norway Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.3.9.3 Target Disease Prevalence
      • 6.3.9.4 Market & Competitive Scenario
      • 6.3.9.5 Regulatory Framework
      • 6.3.9.6 Reimbursement Scenario
      • 6.3.9.7 Rest of Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)s
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Key Country Dynamics
      • 6.4.2.2 Japan Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.4.2.3 Target Disease Prevalence
      • 6.4.2.4 Market & Competitive Scenario
      • 6.4.2.5 Regulatory Framework
      • 6.4.2.6 Reimbursement Scenario
    • 6.4.3 China
      • 6.4.3.1 Key Country Dynamics
      • 6.4.3.2 China Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.4.3.3 Target Disease Prevalence
      • 6.4.3.4 Market & Competitive Scenario
      • 6.4.3.5 Regulatory Framework
      • 6.4.3.6 Reimbursement Scenario
    • 6.4.4 India
      • 6.4.4.1 Key Country Dynamics
      • 6.4.4.2 India Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.4.4.3 Target Disease Prevalence
      • 6.4.4.4 Market & Competitive Scenario
      • 6.4.4.5 Regulatory Framework
      • 6.4.4.6 Reimbursement Scenario
    • 6.4.5 Australia
      • 6.4.5.1 Key Country Dynamics
      • 6.4.5.2 Australia Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.4.5.3 Target Disease Prevalence
      • 6.4.5.4 Market & Competitive Scenario
      • 6.4.5.5 Regulatory Framework & Reimbursement Scenario
    • 6.4.6 Thailand
      • 6.4.6.1 Key Country Dynamics
      • 6.4.6.2 Thailand Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.4.6.3 Target Disease Prevalence
      • 6.4.6.4 Market & Competitive Scenario
      • 6.4.6.5 Regulatory Framework
      • 6.4.6.6 Reimbursement Scenario
    • 6.4.7 South Korea
      • 6.4.7.1 Key Country Dynamics
      • 6.4.7.2 South Korea Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 6.4.7.3 Target Disease Prevalence
      • 6.4.7.4 Market & Competitive Scenario
      • 6.4.7.5 Regulatory Framework/Reimbursement Scenario
      • 6.4.7.6 Rest of Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Key Country Dynamics
      • 6.5.2.2 Brazil Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.2.3 Target Disease Prevalence
      • 6.5.2.4 Market & Competitive Scenario
      • 6.5.2.5 Regulatory Framework
      • 6.5.2.6 Reimbursement Scenario
    • 6.5.3 Mexico
      • 6.5.3.1 Key Country Dynamics
      • 6.5.3.2 Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.3.3 Target Disease Prevalence
      • 6.5.3.4 Market & Competitive Scenario
      • 6.5.3.5 Regulatory Framework
      • 6.5.3.6 Reimbursement Scenario
    • 6.5.4 Argentina
      • 6.5.4.1 Key Country Dynamics
      • 6.5.4.2 Argentina Intravenous Iron Drugs Market Estimates and forecasts, 2018 - 2030 (USD Million)
      • 6.5.4.3 Target Disease Prevalence
      • 6.5.4.4 Market & Competitive Scenario
      • 6.5.4.5 Regulatory Framework
      • 6.5.4.6 Reimbursement Scenario
      • 6.5.4.7 Rest of Latin America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6 MEA
    • 6.6.1 MEA Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million
    • 6.6.2 South Africa
      • 6.6.2.1 Key Country Dynamics
      • 6.6.2.2 South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.2.3 Target Disease Prevalence
      • 6.6.2.4 Market & Competitive Scenario
      • 6.6.2.5 Regulatory Framework
      • 6.6.2.6 Reimbursement Scenario
    • 6.6.3 Saudi Arabia
      • 6.6.3.1 Key Country Dynamics
      • 6.6.3.2 Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.3.3 Target Disease Prevalence
      • 6.6.3.4 Market & Competitive Scenario
      • 6.6.3.5 Regulatory Framework
      • 6.6.3.6 Reimbursement Scenario
    • 6.6.4 UAE
      • 6.6.4.1 Key Country Dynamics
      • 6.6.4.2 UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.4.3 Target Disease Prevalence
      • 6.6.4.4 Market & Competitive Scenario
      • 6.6.4.5 Regulatory Framework
      • 6.6.4.6 Reimbursement Scenario
    • 6.6.5 Kuwait
      • 6.6.5.1 Key Country Dynamics
      • 6.6.5.2 Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.5.3 Target Disease Prevalence
      • 6.6.5.4 Market & Competitive Scenario
      • 6.6.5.5 Regulatory Framework
      • 6.6.5.6 Reimbursement Scenario
      • 6.6.5.7 Rest of MEA Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Company Categorization
  • 7.2 Strategy Mapping
    • 7.2.1 New Product Launch
    • 7.2.2 Partnerships
    • 7.2.3 Acquisition
    • 7.2.4 Collaboration
    • 7.2.5 Funding
  • 7.3 Key Company Market Share Analysis, 2022
  • 7.4 Company Profiles
    • 7.1.1 Allergan, Inc.
      • 7.1.1.1 Company overview
      • 7.1.1.2 Financial performance
      • 7.1.1.3 Product benchmarking
      • 7.1.1.4 Strategic initiatives
    • 7.1.2 AMAG Pharmaceuticals. Inc.
      • 7.1.2.1 Company overview
      • 7.1.2.2 Financial performance
      • 7.1.2.3 Product benchmarking
      • 7.1.2.4 Strategic initiatives
    • 7.1.3 Daiichi Sankyo Company, Ltd.
      • 7.1.3.1 Company overview
      • 7.1.3.2 Financial performance
      • 7.1.3.3 Product benchmarking
      • 7.1.3.4 Strategic initiatives
    • 7.1.4 Sanofi
      • 7.1.4.1 Company overview
      • 7.1.4.2 Financial performance
      • 7.1.4.3 Product benchmarking
      • 7.1.4.4 Strategic initiatives
    • 7.1.5 Fresenius Medical Care AG & Co.
      • 7.1.5.1 Company overview
      • 7.1.5.2 Financial performance
      • 7.1.5.3 Product benchmarking
      • 7.1.5.4 Strategic initiatives
    • 7.1.6 Vifor Pharma Management Ltd.
      • 7.1.6.1 Company overview
      • 7.1.6.2 Financial performance
      • 7.1.6.3 Product benchmarking
      • 7.1.6.4 Strategic initiatives
    • 7.1.7 Pharmacosmos A/S
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic initiatives
    • 7.1.8 Rockwell Medical, Inc.
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic initiatives

Chapter 8 Conclusion

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 15 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 17 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 18 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 19 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 21 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 23 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 25 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 26 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 27 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 32 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 34 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 35 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 36 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 37 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 38 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 39 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 40 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 41 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 42 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 43 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 44 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 45 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 46 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 47 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 49 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 50 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 51 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 52 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 53 MEA intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 54 MEA intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 55 MEA intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 56 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 57 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 60 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 61 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 62 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 63 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Intravenous iron drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation and validation
  • Fig. 9 Commodity flow approach
  • Fig. 10 Market snapshot (USD Million)
  • Fig. 11 Segment snapshot (product & application)
  • Fig. 12 Competitive snapshot
  • Fig. 13 Parent market (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Prevalence of cancer, by type, in 2020 (%)
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 PESTLE analysis
  • Fig. 18 Intravenous iron drugs market: Product outlook and key takeaways
  • Fig. 19 Intravenous iron drugs market: Product movement analysis
  • Fig. 20 Iron dextran market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Iron sucrose market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 FCM market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Intravenous iron drugs market: Application outlook and key takeaways
  • Fig. 25 Intravenous iron drugs market: Application movement analysis
  • Fig. 26 Chronic kidney disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Inflammatory bowel disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Incidence of key cancer types that increase the risk of anemia, 2020 (in thousand)
  • Fig. 30 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Intravenous iron drugs market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 32 Regional marketplace: Key takeaways (1/2)
  • Fig. 33 Regional marketplace: Key takeaways (2/2)
  • Fig. 34 North America intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Key country dynamics
  • Fig. 36 U.S. intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Cancer incidence, 2022 and 2030
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Cancer incidence, 2018 - 2030
  • Fig. 41 Europe intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Cancer incidence, 2018 - 2030
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Cancer incidence, 2018 - 2030
  • Fig. 48 Key country dynamics
  • Fig. 49 France intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Cancer incidence, 2018 - 2030
  • Fig. 51 Key country dynamics
  • Fig. 52 Italy intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Cancer incidence, 2018 - 2030
  • Fig. 54 Key country dynamics
  • Fig. 55 Spain intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Cancer incidence, 2018 - 2030
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Target disease prevalence
  • Fig. 60 Key country dynamics
  • Fig. 61 Sweden intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Five most common cancers in Sweden
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Number of new cancer cases in 2020, both sexes, all ages
  • Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Number of new cases in 2020, both sexes, all ages
  • Fig. 71 Key country dynamics
  • Fig. 72 China intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Cancer incidence, 2018 to 2030
  • Fig. 74 Key country dynamics
  • Fig. 75 India intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Cancer incidence, 2018 to 2030
  • Fig. 77 Key country dynamics
  • Fig. 78 Australia intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Cancer incidence, 2018 to 2030
  • Fig. 80 Key country dynamics
  • Fig. 81 Thailand intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Cancer incidence, 2020 to 2030
  • Fig. 83 Key country dynamics
  • Fig. 84 South Korea intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Cancer incidence 2018 to 2030
  • Fig. 86 Rest of Asia Pacific intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 Latin America intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Brazil intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Estimated number of new cancer cases in Brazil
  • Fig. 91 Key country dynamics
  • Fig. 92 Mexico intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Estimated number of new cancer cases in Mexico
  • Fig. 94 Key country dynamics
  • Fig. 95 Argentina intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Estimated number of new cancer cases in Argentina
  • Fig. 97 Rest of Latin America intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 MEA intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 South Africa intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Cancer prevalence -2018 - 2030
  • Fig. 102 Key country dynamics
  • Fig. 103 Saudi Arabia intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Cancer prevalence - 2018 - 2030
  • Fig. 105 Key country dynamics
  • Fig. 106 UAE intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Cancer prevalence-2018 - 2030
  • Fig. 108 Key country dynamics
  • Fig. 109 Kuwait intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Target disease prevalence
  • Fig. 111 Rest of MEA intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Market participant categorization
  • Fig. 113 Company market share analysis, 2023
  • Fig. 114 Strategic framework